Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Dinutuximab met chemotherapie, chirurgie en stamceltransplantatie voor de behandeling van kinderen met nieuw gediagnosticeerd hoogrisico-neuroblastoom

29 oktober 2026 bijgewerkt door: National Cancer Institute (NCI)

Een fase 3-studie van dinutuximab toegevoegd aan intensieve multimodale therapie voor kinderen met nieuw gediagnosticeerd hoogrisiconeuroblastoom

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.

Studie Overzicht

Gedetailleerde beschrijving

PRIMARY OBJECTIVE:

I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.

SECONDARY OBJECTIVES:

I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.

II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.

III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.

IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.

EXPLORATORY OBJECTIVES:

I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.

II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.

III. To compare patterns of failure between patients treated with and without dinutuximab during induction.

IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.

V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.

VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.

VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.

VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.

XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.

XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.

XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).

XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.

XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.

OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.

INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.

ARM A:

INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.

EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.

CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.

POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.

Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.

ARM B:

INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.

EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.

CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.

POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.

Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.

After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.

Studietype

Ingrijpend

Inschrijving (Geschat)

478

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • New South Wales
      • Randwick, New South Wales, Australië, 2031
        • Werving
        • Sydney Children's Hospital
        • Hoofdonderzoeker:
          • Draga Barbaric
        • Contact:
          • Site Public Contact
          • Telefoonnummer: (02) 9382-1721
      • Westmead, New South Wales, Australië, 2145
        • Werving
        • The Children's Hospital at Westmead
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 61-2-9845 1400
        • Hoofdonderzoeker:
          • Bhavna Padhye
    • Queensland
      • South Brisbane, Queensland, Australië, 4101
        • Werving
        • Queensland Children's Hospital
        • Hoofdonderzoeker:
          • Steven A. Foresto
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 61 7 3068 1111
    • Victoria
      • Parkville, Victoria, Australië, 3052
        • Werving
        • Royal Children's Hospital
        • Hoofdonderzoeker:
          • Martin A. Campbell
        • Contact:
    • Western Australia
      • Perth, Western Australia, Australië, 6009
      • Québec, Canada, G1V 4G2
        • Werving
        • CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
        • Hoofdonderzoeker:
          • Bruno Michon
        • Contact:
    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Werving
        • Alberta Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Victor A. Lewis
      • Edmonton, Alberta, Canada, T6G 2B7
        • Werving
        • University of Alberta Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Sarah J. McKillop
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • Werving
        • British Columbia Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 6477 604-875-2345
        • Hoofdonderzoeker:
          • Rebecca J. Deyell
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Werving
        • CancerCare Manitoba
        • Contact:
        • Hoofdonderzoeker:
          • Stephanie M. Villeneuve
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
        • Werving
        • Janeway Child Health Centre
        • Hoofdonderzoeker:
          • Lisa A. Goodyear
        • Contact:
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 6R8
        • Werving
        • IWK Health Centre
        • Contact:
        • Hoofdonderzoeker:
          • Chelsea Ash
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • Werving
        • McMaster Children's Hospital at Hamilton Health Sciences
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 905-521-2100
        • Hoofdonderzoeker:
          • Uma H. Athale
      • London, Ontario, Canada, N6A 5W9
        • Werving
        • Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 519-685-8306
        • Hoofdonderzoeker:
          • Shayna M. Zelcer
      • Ottawa, Ontario, Canada, K1H 8L1
        • Werving
        • Children's Hospital of Eastern Ontario
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 613-737-7600
        • Hoofdonderzoeker:
          • Donna L. Johnston
      • Toronto, Ontario, Canada, M5G 1X8
        • Werving
        • Hospital for Sick Children
        • Contact:
        • Hoofdonderzoeker:
          • Daniel A. Morgenstern
    • Quebec
      • Montreal, Quebec, Canada, H3H 1P3
        • Werving
        • The Montreal Children's Hospital of the MUHC
        • Contact:
        • Hoofdonderzoeker:
          • Stephanie Mourad
      • Montreal, Quebec, Canada, H3T 1C5
        • Werving
        • Centre Hospitalier Universitaire Sainte-Justine
        • Hoofdonderzoeker:
          • Monia Marzouki
        • Contact:
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Werving
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
        • Contact:
        • Hoofdonderzoeker:
          • Stephanie Vairy
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7N 0W8
    • Auckland
      • Grafton, Auckland, Nieuw-Zeeland, 1145
        • Werving
        • Starship Children's Hospital
        • Hoofdonderzoeker:
          • Andrew C. Wood
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 0800 728 436
      • San Juan, Puerto Rico, 00926
        • Werving
        • University Pediatric Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 787-474-0333
        • Hoofdonderzoeker:
          • Maria E. Echevarria
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35233
        • Werving
        • Children's Hospital of Alabama
        • Contact:
        • Hoofdonderzoeker:
          • Elizabeth D. Alva
      • Mobile, Alabama, Verenigde Staten, 36604
        • Werving
        • USA Health Strada Patient Care Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-388-8721
        • Hoofdonderzoeker:
          • Hamayun Imran
    • Arizona
      • Mesa, Arizona, Verenigde Staten, 85202
        • Werving
        • Banner Children's at Desert
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 480-412-3100
        • Hoofdonderzoeker:
          • Joseph C. Torkildson
      • Phoenix, Arizona, Verenigde Staten, 85016
        • Werving
        • Phoenix Childrens Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 602-546-0920
        • Hoofdonderzoeker:
          • Alok K. Kothari
      • Tucson, Arizona, Verenigde Staten, 85719
        • Werving
        • Banner University Medical Center - Tucson
        • Contact:
        • Hoofdonderzoeker:
          • Monica M. Davini
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72202-3591
        • Werving
        • Arkansas Children's Hospital
        • Hoofdonderzoeker:
          • Michael W. Bishop
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 501-364-7373
    • California
      • Downey, California, Verenigde Staten, 90242
        • Werving
        • Kaiser Permanente Downey Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 626-564-3455
        • Hoofdonderzoeker:
          • Robert M. Cooper
      • Duarte, California, Verenigde Staten, 91010
        • Werving
        • City of Hope Comprehensive Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Hung C. Tran
      • Loma Linda, California, Verenigde Staten, 92354
        • Werving
        • Loma Linda University Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 909-558-4050
        • Hoofdonderzoeker:
          • Albert Kheradpour
      • Long Beach, California, Verenigde Staten, 90806
        • Werving
        • Miller Children's and Women's Hospital Long Beach
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 562-933-5600
        • Hoofdonderzoeker:
          • Jacqueline N. Casillas
      • Los Angeles, California, Verenigde Staten, 90027
        • Werving
        • Children's Hospital Los Angeles
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 323-361-4110
        • Hoofdonderzoeker:
          • Araz Marachelian
      • Los Angeles, California, Verenigde Staten, 90048
        • Werving
        • Cedars-Sinai Medical Center
        • Hoofdonderzoeker:
          • Fataneh (Fae) Majlessipour
        • Contact:
      • Los Angeles, California, Verenigde Staten, 90095
        • Werving
        • Mattel Children's Hospital UCLA
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 310-825-6708
        • Hoofdonderzoeker:
          • Satiro N. De Oliveira
      • Madera, California, Verenigde Staten, 93636
        • Werving
        • Valley Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Ruetima Titapiwatanakun
      • Oakland, California, Verenigde Staten, 94611
        • Werving
        • Kaiser Permanente-Oakland
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Hoofdonderzoeker:
          • Aarati V. Rao
      • Oakland, California, Verenigde Staten, 94609
        • Werving
        • UCSF Benioff Children's Hospital Oakland
        • Hoofdonderzoeker:
          • Jennifer G. Michlitsch
        • Contact:
      • Orange, California, Verenigde Staten, 92868
        • Werving
        • Children's Hospital of Orange County
        • Contact:
        • Hoofdonderzoeker:
          • Elyssa M. Rubin
      • Palo Alto, California, Verenigde Staten, 94304
        • Werving
        • Lucile Packard Children's Hospital Stanford University
        • Contact:
        • Hoofdonderzoeker:
          • Jay Michael S. Balagtas
      • Sacramento, California, Verenigde Staten, 95817
        • Werving
        • University of California Davis Comprehensive Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 916-734-3089
        • Hoofdonderzoeker:
          • Marcio H. Malogolowkin
      • Sacramento, California, Verenigde Staten, 95816
      • San Diego, California, Verenigde Staten, 92123
        • Werving
        • Rady Children's Hospital - San Diego
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 858-966-5934
        • Hoofdonderzoeker:
          • William D. Roberts
      • San Francisco, California, Verenigde Staten, 94158
        • Werving
        • UCSF Medical Center-Mission Bay
        • Contact:
        • Hoofdonderzoeker:
          • Arun A. Rangaswami
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • Children's Hospital Colorado
        • Hoofdonderzoeker:
          • Navin R. Pinto
        • Contact:
    • Connecticut
      • Hartford, Connecticut, Verenigde Staten, 06106
        • Werving
        • Connecticut Children's Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 860-545-9981
        • Hoofdonderzoeker:
          • Michael S. Isakoff
      • New Haven, Connecticut, Verenigde Staten, 06520
        • Werving
        • Yale University
        • Contact:
        • Hoofdonderzoeker:
          • Farzana Pashankar
    • Delaware
      • Wilmington, Delaware, Verenigde Staten, 19803
        • Werving
        • Alfred I duPont Hospital for Children
        • Contact:
        • Hoofdonderzoeker:
          • Sridhi Patel
    • District of Columbia
      • Washington D.C., District of Columbia, Verenigde Staten, 20010
        • Werving
        • Children's National Medical Center
        • Hoofdonderzoeker:
          • Jeffrey S. Dome
        • Contact:
    • Florida
      • Fort Lauderdale, Florida, Verenigde Staten, 33316
        • Werving
        • Broward Health Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Hector M. Rodriguez-Cortes
      • Fort Myers, Florida, Verenigde Staten, 33908
        • Werving
        • Golisano Children's Hospital of Southwest Florida
        • Contact:
        • Hoofdonderzoeker:
          • Emad K. Salman
      • Gainesville, Florida, Verenigde Staten, 32610
        • Werving
        • UF Health Cancer Institute - Gainesville
        • Contact:
        • Hoofdonderzoeker:
          • Brian Stover
      • Hollywood, Florida, Verenigde Staten, 33021
        • Werving
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 954-265-1847
          • E-mail: OHR@mhs.net
        • Hoofdonderzoeker:
          • Iftikhar Hanif
      • Jacksonville, Florida, Verenigde Staten, 32207
        • Werving
        • Nemours Children's Clinic-Jacksonville
        • Contact:
        • Hoofdonderzoeker:
          • Sridhi Patel
      • Miami, Florida, Verenigde Staten, 33155
        • Werving
        • Nicklaus Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 888-624-2778
        • Hoofdonderzoeker:
          • Ziad A. Khatib
      • Miami, Florida, Verenigde Staten, 33136
        • Werving
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 305-243-2647
        • Hoofdonderzoeker:
          • Meghan McCormick
      • Orlando, Florida, Verenigde Staten, 32806
        • Werving
        • Arnold Palmer Hospital for Children
        • Contact:
        • Hoofdonderzoeker:
          • Zhongbo Hu
      • Orlando, Florida, Verenigde Staten, 32827
        • Werving
        • Nemours Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Sridhi Patel
      • Orlando, Florida, Verenigde Staten, 32803
        • Werving
        • AdventHealth Orlando
        • Contact:
        • Hoofdonderzoeker:
          • Fouad M. Hajjar
      • St. Petersburg, Florida, Verenigde Staten, 33701
        • Werving
        • Johns Hopkins All Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Jennifer B. Dean
      • West Palm Beach, Florida, Verenigde Staten, 33407
        • Werving
        • Saint Mary's Medical Center
        • Hoofdonderzoeker:
          • Matthew D. Ramirez
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 561-822-4745
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30329
        • Werving
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
        • Hoofdonderzoeker:
          • William T. Cash
        • Contact:
      • Savannah, Georgia, Verenigde Staten, 31404
        • Werving
        • Memorial Health University Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • James N. Yarnall
    • Hawaii
      • Honolulu, Hawaii, Verenigde Staten, 96826
        • Werving
        • Kapiolani Medical Center for Women and Children
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 808-983-6090
        • Hoofdonderzoeker:
          • Wade T. Kyono
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Werving
        • Lurie Children's Hospital-Chicago
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 773-880-4562
        • Hoofdonderzoeker:
          • Elizabeth A. Sokol
      • Chicago, Illinois, Verenigde Staten, 60637
        • Werving
        • University of Chicago Comprehensive Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Ami V. Desai
      • Chicago, Illinois, Verenigde Staten, 60612
        • Werving
        • University of Illinois
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 312-355-3046
        • Hoofdonderzoeker:
          • Dipti S. Dighe
      • Oak Lawn, Illinois, Verenigde Staten, 60453
        • Werving
        • Advocate Children's Hospital-Oak Lawn
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 847-723-7570
        • Hoofdonderzoeker:
          • Rebecca E. McFall
      • Park Ridge, Illinois, Verenigde Staten, 60068
      • Peoria, Illinois, Verenigde Staten, 61637
      • Springfield, Illinois, Verenigde Staten, 62702
        • Werving
        • Southern Illinois University School of Medicine
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 217-545-7929
        • Hoofdonderzoeker:
          • Gregory P. Brandt
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Werving
        • Riley Hospital for Children
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-248-1199
        • Hoofdonderzoeker:
          • Marissa Just
      • Indianapolis, Indiana, Verenigde Staten, 46260
        • Werving
        • Ascension Saint Vincent Indianapolis Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Bassem I. Razzouk
    • Iowa
      • Des Moines, Iowa, Verenigde Staten, 50309
        • Werving
        • Blank Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Samantha L. Mallory
      • Iowa City, Iowa, Verenigde Staten, 52242
        • Werving
        • University of Iowa/Holden Comprehensive Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-237-1225
        • Hoofdonderzoeker:
          • Andrew P. Groves
    • Kansas
      • Wichita, Kansas, Verenigde Staten, 67214
        • Werving
        • Wesley Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Nathan S. Hall
    • Kentucky
      • Lexington, Kentucky, Verenigde Staten, 40536
        • Werving
        • University of Kentucky/Markey Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 859-257-3379
        • Hoofdonderzoeker:
          • James T. Badgett
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Werving
        • Norton Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Michael J. Ferguson
    • Louisiana
      • New Orleans, Louisiana, Verenigde Staten, 70118
        • Werving
        • Children's Hospital New Orleans
        • Hoofdonderzoeker:
          • Maria C. Velez-Yanguas
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 504-894-5377
    • Maine
      • Bangor, Maine, Verenigde Staten, 04401
        • Werving
        • Eastern Maine Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 207-973-4274
        • Hoofdonderzoeker:
          • Daniel L. Callaway
      • Scarborough, Maine, Verenigde Staten, 04074
        • Werving
        • Maine Children's Cancer Program
        • Hoofdonderzoeker:
          • Sei-Gyung K. Sze
        • Contact:
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21287
        • Werving
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Hoofdonderzoeker:
          • Allen R. Chen
        • Contact:
      • Baltimore, Maryland, Verenigde Staten, 21215
        • Werving
        • Sinai Hospital of Baltimore
        • Hoofdonderzoeker:
          • Jason M. Fixler
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 410-601-9083
      • Baltimore, Maryland, Verenigde Staten, 21201
        • Werving
        • University of Maryland/Greenebaum Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-888-8823
        • Hoofdonderzoeker:
          • Teresa A. York
      • Bethesda, Maryland, Verenigde Staten, 20889-5600
        • Werving
        • Walter Reed National Military Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 301-319-2100
        • Hoofdonderzoeker:
          • Kip R. Hartman
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Werving
        • Massachusetts General Hospital Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 877-726-5130
        • Hoofdonderzoeker:
          • Lauren H. Boal
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Werving
        • Dana-Farber Cancer Institute
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 877-442-3324
        • Hoofdonderzoeker:
          • Suzanne Shusterman
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • Werving
        • C S Mott Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-865-1125
        • Hoofdonderzoeker:
          • Rajen Mody
      • Detroit, Michigan, Verenigde Staten, 48201
        • Geschorst
        • Children's Hospital of Michigan
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Werving
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Verenigde Staten, 49007
        • Werving
        • Bronson Methodist Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Royal Oak, Michigan, Verenigde Staten, 48073
        • Werving
        • Corewell Health Children's
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 248-551-7695
        • Hoofdonderzoeker:
          • Marie V. Nelson
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55404
        • Werving
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
        • Hoofdonderzoeker:
          • Michael K. Richards
        • Contact:
      • Minneapolis, Minnesota, Verenigde Staten, 55455
        • Werving
        • University of Minnesota/Masonic Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 612-624-2620
        • Hoofdonderzoeker:
          • Robin L. Williams
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Werving
        • Mayo Clinic in Rochester
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 855-776-0015
        • Hoofdonderzoeker:
          • Peter Schoettler
    • Mississippi
      • Jackson, Mississippi, Verenigde Staten, 39216
        • Werving
        • University of Mississippi Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 601-815-6700
        • Hoofdonderzoeker:
          • Amanda Strobel
    • Missouri
      • Columbia, Missouri, Verenigde Staten, 65212
        • Werving
        • University of Missouri Children's Hospital
        • Hoofdonderzoeker:
          • Barbara A. Gruner
        • Contact:
      • Kansas City, Missouri, Verenigde Staten, 64108
        • Werving
        • Children's Mercy Hospitals and Clinics
        • Hoofdonderzoeker:
          • Keith J. August
        • Contact:
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • Washington University School of Medicine
        • Contact:
        • Hoofdonderzoeker:
          • Frederick S. Huang
      • St Louis, Missouri, Verenigde Staten, 63141
        • Werving
        • Mercy Hospital Saint Louis
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 314-251-7066
        • Hoofdonderzoeker:
          • Robin D. Hanson
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68114
        • Werving
        • Children's Hospital and Medical Center of Omaha
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 402-955-3949
        • Hoofdonderzoeker:
          • Jill C. Beck
      • Omaha, Nebraska, Verenigde Staten, 68198
        • Werving
        • University of Nebraska Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Jill C. Beck
    • Nevada
      • Las Vegas, Nevada, Verenigde Staten, 89135
        • Werving
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
        • Contact:
        • Hoofdonderzoeker:
          • Joseph L. Lasky
    • New Hampshire
      • Lebanon, New Hampshire, Verenigde Staten, 03756
        • Werving
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Hoofdonderzoeker:
          • Angela Ricci
        • Contact:
    • New Jersey
      • Hackensack, New Jersey, Verenigde Staten, 07601
        • Werving
        • Hackensack University Medical Center
        • Hoofdonderzoeker:
          • Katharine Offer
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 551-996-2897
      • Morristown, New Jersey, Verenigde Staten, 07960
        • Werving
        • Morristown Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 973-971-5900
        • Hoofdonderzoeker:
          • Kathryn L. Laurie
      • New Brunswick, New Jersey, Verenigde Staten, 08901
        • Werving
        • Saint Peter's University Hospital
        • Hoofdonderzoeker:
          • Nibal A. Zaghloul
        • Contact:
      • New Brunswick, New Jersey, Verenigde Staten, 08903
        • Werving
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 732-235-8675
        • Hoofdonderzoeker:
          • Nehal S. Parikh
      • Newark, New Jersey, Verenigde Staten, 07112
        • Werving
        • Newark Beth Israel Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Teena Bhatla
      • Paterson, New Jersey, Verenigde Staten, 07503
        • Werving
        • Saint Joseph's Regional Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Alissa Kahn
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 87106
        • Geschorst
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Verenigde Staten, 12208
        • Werving
        • Albany Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 518-262-5513
        • Hoofdonderzoeker:
          • Lauren R. Weintraub
      • Buffalo, New York, Verenigde Staten, 14263
        • Werving
        • Roswell Park Cancer Institute
        • Contact:
        • Hoofdonderzoeker:
          • Clare J. Twist
      • Mineola, New York, Verenigde Staten, 11501
        • Werving
        • NYU Langone Hospital - Long Island
        • Contact:
        • Hoofdonderzoeker:
          • Chana L. Glasser
      • New Hyde Park, New York, Verenigde Staten, 11040
        • Werving
        • The Steven and Alexandra Cohen Children's Medical Center of New York
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 718-470-3460
        • Hoofdonderzoeker:
          • Julie I. Krystal
      • New York, New York, Verenigde Staten, 10032
        • Werving
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Hoofdonderzoeker:
          • Nobuko Hijiya
        • Contact:
      • New York, New York, Verenigde Staten, 10016
        • Werving
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • Hoofdonderzoeker:
          • Elizabeth A. Raetz
        • Contact:
      • Rochester, New York, Verenigde Staten, 14642
        • Werving
        • University of Rochester
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 585-275-5830
        • Hoofdonderzoeker:
          • Rafi R. Kazi
      • Syracuse, New York, Verenigde Staten, 13210
        • Werving
        • State University of New York Upstate Medical University
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 315-464-5476
        • Hoofdonderzoeker:
          • Melanie A. Comito
      • The Bronx, New York, Verenigde Staten, 10467
        • Werving
        • Montefiore Medical Center - Moses Campus
        • Contact:
        • Hoofdonderzoeker:
          • Alice Lee
      • Valhalla, New York, Verenigde Staten, 10595
        • Werving
        • New York Medical College
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 914-594-3794
        • Hoofdonderzoeker:
          • Andrew J. Bellantoni
    • North Carolina
      • Asheville, North Carolina, Verenigde Staten, 28801
      • Chapel Hill, North Carolina, Verenigde Staten, 27599
        • Werving
        • UNC Lineberger Comprehensive Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Thomas B. Alexander
      • Charlotte, North Carolina, Verenigde Staten, 28203
        • Werving
        • Carolinas Medical Center/Levine Cancer Institute
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-9376
        • Hoofdonderzoeker:
          • Joel A. Kaplan
      • Charlotte, North Carolina, Verenigde Staten, 28204
        • Werving
        • Novant Health Presbyterian Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Holly Edington
      • Durham, North Carolina, Verenigde Staten, 27710
        • Werving
        • Duke University Medical Center
        • Hoofdonderzoeker:
          • Jessica M. Sun
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 888-275-3853
      • Greenville, North Carolina, Verenigde Staten, 27834
        • Werving
        • East Carolina University
        • Contact:
        • Hoofdonderzoeker:
          • Andrea R. Whitfield
      • Winston-Salem, North Carolina, Verenigde Staten, 27157
        • Werving
        • Wake Forest University Health Sciences
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 336-713-6771
        • Hoofdonderzoeker:
          • Sarah Supples
    • North Dakota
      • Fargo, North Dakota, Verenigde Staten, 58122
    • Ohio
      • Akron, Ohio, Verenigde Staten, 44308
        • Werving
        • Children's Hospital Medical Center of Akron
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 330-543-3193
        • Hoofdonderzoeker:
          • Lauren R. Draper
      • Cincinnati, Ohio, Verenigde Staten, 45229
        • Werving
        • Cincinnati Children's Hospital Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Katherine M. Somers
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Werving
        • Cleveland Clinic Foundation
        • Contact:
        • Hoofdonderzoeker:
          • Matteo M. Trucco
      • Cleveland, Ohio, Verenigde Staten, 44106
        • Werving
        • Rainbow Babies and Childrens Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 216-844-5437
        • Hoofdonderzoeker:
          • Duncan S. Stearns
      • Columbus, Ohio, Verenigde Staten, 43205
      • Dayton, Ohio, Verenigde Staten, 45404
        • Werving
        • Dayton Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-228-4055
        • Hoofdonderzoeker:
          • Jordan M. Wright
      • Toledo, Ohio, Verenigde Staten, 43606
        • Werving
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Jamie L. Dargart
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Werving
        • University of Oklahoma Health Sciences Center
        • Contact:
        • Hoofdonderzoeker:
          • Rene Y. McNall-Knapp
      • Tulsa, Oklahoma, Verenigde Staten, 74136
        • Werving
        • Saint Francis Children's Hospital
        • Hoofdonderzoeker:
          • Jill A. Salo
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 918-502-6720
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97227
        • Werving
        • Legacy Emanuel Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 503-413-2560
        • Hoofdonderzoeker:
          • Jason M. Glover
      • Portland, Oregon, Verenigde Staten, 97239
        • Werving
        • Oregon Health and Science University
        • Contact:
        • Hoofdonderzoeker:
          • Susan J. Lindemulder
    • Pennsylvania
      • Allentown, Pennsylvania, Verenigde Staten, 18103
        • Werving
        • Lehigh Valley Hospital-Cedar Crest
        • Contact:
        • Hoofdonderzoeker:
          • Jacob A. Troutman
      • Danville, Pennsylvania, Verenigde Staten, 17822
        • Werving
        • Geisinger Medical Center
        • Hoofdonderzoeker:
          • Jagadeesh Ramdas
        • Contact:
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Werving
        • Children's Hospital of Philadelphia
        • Hoofdonderzoeker:
          • Rochelle Bagatell
        • Contact:
      • Philadelphia, Pennsylvania, Verenigde Staten, 19134
        • Werving
        • Saint Christopher's Hospital for Children
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 215-427-8991
        • Hoofdonderzoeker:
          • Gregory E. Halligan
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15224
        • Werving
        • Children's Hospital of Pittsburgh of UPMC
        • Contact:
        • Hoofdonderzoeker:
          • Jean M. Tersak
    • Rhode Island
      • Providence, Rhode Island, Verenigde Staten, 02903
        • Werving
        • Rhode Island Hospital
        • Hoofdonderzoeker:
          • Bradley DeNardo
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 401-444-1488
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Werving
        • Medical University of South Carolina
        • Contact:
        • Hoofdonderzoeker:
          • Jacqueline M. Kraveka
      • Columbia, South Carolina, Verenigde Staten, 29203
        • Werving
        • Prisma Health Richland Hospital
        • Hoofdonderzoeker:
          • Stuart L. Cramer
        • Contact:
      • Greenville, South Carolina, Verenigde Staten, 29605
        • Werving
        • BI-LO Charities Children's Cancer Center
        • Hoofdonderzoeker:
          • Aniket Saha
        • Contact:
    • South Dakota
      • Sioux Falls, South Dakota, Verenigde Staten, 57117-5134
    • Tennessee
      • Knoxville, Tennessee, Verenigde Staten, 37916
        • Werving
        • East Tennessee Childrens Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 865-541-8266
        • Hoofdonderzoeker:
          • Susan E. Spiller
      • Memphis, Tennessee, Verenigde Staten, 38105
        • Werving
        • Saint Jude Children's Research Hospital
        • Hoofdonderzoeker:
          • Sara M. Federico
        • Contact:
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Werving
        • Vanderbilt University/Ingram Cancer Center
        • Hoofdonderzoeker:
          • Daniel J. Benedetti
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-811-8480
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • The Children's Hospital at TriStar Centennial
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 615-342-1919
        • Hoofdonderzoeker:
          • Clinton M. Carroll
    • Texas
      • Austin, Texas, Verenigde Staten, 78723
      • Corpus Christi, Texas, Verenigde Staten, 78411
        • Werving
        • Driscoll Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Nkechi I. Mba
      • Dallas, Texas, Verenigde Staten, 75390
        • Werving
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Hoofdonderzoeker:
          • Tanya C. Watt
        • Contact:
      • Dallas, Texas, Verenigde Staten, 75230
        • Werving
        • Medical City Dallas Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 972-566-5588
        • Hoofdonderzoeker:
          • Maurizio L. Ghisoli
      • El Paso, Texas, Verenigde Staten, 79905
        • Werving
        • El Paso Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Benjamin Carcamo
      • Fort Worth, Texas, Verenigde Staten, 76104
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 713-798-1354
          • E-mail: burton@bcm.edu
        • Hoofdonderzoeker:
          • Jennifer H. Foster
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • UT MD Anderson Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Najat C. Daw
      • Lubbock, Texas, Verenigde Staten, 79410
        • Werving
        • Covenant Children's Hospital
        • Hoofdonderzoeker:
          • Kishor M. Bhende
        • Contact:
      • Lubbock, Texas, Verenigde Staten, 79415
        • Werving
        • UMC Cancer Center / UMC Health System
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 806-775-8590
        • Hoofdonderzoeker:
          • Erin K. Barr
      • San Antonio, Texas, Verenigde Staten, 78207
        • Werving
        • Children's Hospital of San Antonio
        • Contact:
        • Hoofdonderzoeker:
          • Julie Voeller
      • San Antonio, Texas, Verenigde Staten, 78229
        • Werving
        • University of Texas Health Science Center at San Antonio
        • Contact:
        • Hoofdonderzoeker:
          • Aaron J. Sugalski
      • San Antonio, Texas, Verenigde Staten, 78229
        • Werving
        • Methodist Children's Hospital of South Texas
        • Contact:
        • Hoofdonderzoeker:
          • Jose M. Esquilin
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84113
        • Werving
        • Primary Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 801-585-5270
        • Hoofdonderzoeker:
          • Leonora R. Slatnick
    • Vermont
      • Burlington, Vermont, Verenigde Staten, 05405
        • Werving
        • University of Vermont and State Agricultural College
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 802-656-8990
          • E-mail: rpo@uvm.edu
        • Hoofdonderzoeker:
          • Jessica L. Heath
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22908
      • Portsmouth, Virginia, Verenigde Staten, 23708-2197
        • Werving
        • Naval Medical Center - Portsmouth
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 757-953-5939
        • Hoofdonderzoeker:
          • Karin Brockman
    • Washington
      • Seattle, Washington, Verenigde Staten, 98105
        • Werving
        • Seattle Children's Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 866-987-2000
        • Hoofdonderzoeker:
          • Sarah E. Leary
      • Spokane, Washington, Verenigde Staten, 99204
        • Werving
        • Providence Sacred Heart Medical Center and Children's Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Judy L. Felgenhauer
      • Tacoma, Washington, Verenigde Staten, 98405
        • Werving
        • Mary Bridge Children's Hospital and Health Center
        • Contact:
        • Hoofdonderzoeker:
          • Robert G. Irwin
    • West Virginia
      • Huntington, West Virginia, Verenigde Staten, 25701
        • Werving
        • Edwards Comprehensive Cancer Center
        • Hoofdonderzoeker:
          • Mark A. Ranalli
        • Contact:
      • Morgantown, West Virginia, Verenigde Staten, 26506
        • Werving
        • West Virginia University Healthcare
        • Contact:
        • Hoofdonderzoeker:
          • Ashley E. Meyer
    • Wisconsin
      • Green Bay, Wisconsin, Verenigde Staten, 54301
        • Geschorst
        • Saint Vincent Hospital Cancer Center Green Bay
      • Madison, Wisconsin, Verenigde Staten, 53792
        • Werving
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Margo L. Hoover-Regan
      • Marshfield, Wisconsin, Verenigde Staten, 54449
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Werving
        • Children's Hospital of Wisconsin
        • Hoofdonderzoeker:
          • Angela Steineck
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

Niet ouder dan 30 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131

  • ≤ 30 years at the time of initial diagnosis with high-risk disease

  • * Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines

    • Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:

      • Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
      • Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
      • Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
      • Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
  • Patients must have a body surface area (BSA) ≥ 0.25 m^2

  • No prior anti-cancer therapy except as outlined below:

    • Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
    • Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
    • Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
  • Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • A serum creatinine based on age/sex as follows:

    • 1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL

    • 6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL

    • 1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL

    • 2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL

    • 6 to < 10 years: Male 1 mg/dL and female 1 mg/dL

    • 10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL

    • 13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL

    • ≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL

      • The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
    • or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or

    • or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)

      • Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age

  • Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
  • * Shortening fraction of ≥ 27% by echocardiogram, or

    • Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
  • Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:

No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure

Exclusion Criteria:

  • Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
  • Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
  • Patients with known bone marrow failure syndromes
  • Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
  • Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
  • Lactating females who plan to breastfeed their infants
  • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Arm A (SOC treatment)

See detailed description

Given IV

Andere namen:
  • Blastocarb
  • Carboplat
  • Carboplatine Hexal
  • Carboplatino
  • Carboplatina
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatine
  • Paraplatina AQ
  • Platinawas
  • Ribocarbo
  • JM8

Given IV

Andere namen:
  • Cytoxaan
  • CTX
  • (-)-cyclofosfamide
  • 2H-1,3,2-Oxazafosforine, 2-[bis(2-chloorethyl)amino]tetrahydro-, 2-oxide, monohydraat
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Clafeen
  • CP monohydraat
  • CYCLO-cel
  • Cycloblastine
  • Cyclofosfam
  • Cyclofosfamide-monohydraat
  • Cyclofosfamidum
  • Cyclofosfan
  • Cyclofosfaan
  • Cyclofosfanum
  • Cyclostine
  • Cytofosfan
  • Cytofosfaan
  • Fosfaseron
  • Genoxal
  • Genuxaal
  • Ledoxine
  • Mitoxan
  • Neosar
  • Opwekken
  • Syklofosfamide
  • WR-138719
  • Asta B 518
  • B-518
  • B518
  • WR138719
  • Frindovyx

Given IV

Andere namen:
  • CDDP
  • Cis-diamminedichloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatine
  • Platina
  • Abiplatine
  • Blastolem
  • Briplatine
  • Cis-diammine-dichloorplatina
  • Cis-diamminedichloor Platina (II)
  • Cis-diamminedichloorplatina
  • Cis-dichlooramine platina (II)
  • Cis-platina Diamine Dichloride
  • Cis-platina
  • Cis-platina II
  • Cis-platina II diaminedichloride
  • Cisplatine
  • Cisplatyl
  • Citoplatina
  • Citosine
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatine
  • Chloride van Peyrone
  • Zout van Peyrone
  • Plaats
  • Kunststof
  • Platamine
  • Platiblastine
  • Platiblastine-S
  • Platinex
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxaan
  • Platina diamminodichloride
  • Platiraans
  • Platistine
  • Platosine

Undergo bone marrow biopsy

Andere namen:
  • Biopsie van beenmerg
  • Biopsie, beenmerg

Given IV

Andere namen:
  • Adriablastine
  • Hydroxydaunomycine
  • Hydroxyl Daunorubicine
  • Hydroxyldaunorubicine

Given IV

Andere namen:
  • Videorecorder
  • Leurocristine
  • Vincristine
  • LCR

Undergo MRI

Andere namen:
  • MRI
  • Magnetische resonantie
  • Magnetic Resonance Imaging-scan
  • Medische beeldvorming, magnetische resonantie / nucleaire magnetische resonantie
  • DHR
  • MR-beeldvorming
  • MRI scan
  • NMR-beeldvorming
  • NMRI
  • Nucleaire magnetische resonantie beeldvorming
  • Magnetische resonantiebeeldvorming (MRI)
  • sMRI
  • Magnetische resonantiebeeldvorming (procedure)
  • MRI's
  • Structurele MRI

Undergo ECHO

Andere namen:
  • Echocardiografie
  • EG

Undergo MUGA

Andere namen:
  • Blood Pool-scan
  • Equilibrium radionuclide angiografie
  • Gated Blood Pool-beeldvorming
  • MUGA
  • Radionuclide ventriculografie
  • RNVG
  • SYMA scannen
  • Gesynchroniseerde Multigated Acquisitie Scannen
  • MUGA-scan
  • Multi-Gated Acquisitie Scan
  • Radionuclide ventriculogram scan
  • Gated Heart Pool-scan
  • RNV-scan

Undergo bone marrow aspiration

Given IV

Andere namen:
  • Demethyl Epipodofyllotoxine Ethylidine Glucoside
  • EPEG
  • Laatste
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type

Given IV

Andere namen:
  • Hycamptamine
  • Topotecan lacton

Undergo radiation therapy

Andere namen:
  • Radiotherapie bij kanker
  • ENERGY_TYPE
  • Bestralen
  • Bestraald
  • Bestraling
  • Straling
  • Radiotherapie, NOS
  • Radiotherapie
  • RT
  • Therapie, bestraling
  • Energie Type

Undergo blood and urine sample collection

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling

Ancillary studies

Given IV

Andere namen:
  • CB-3025
  • L-PAM
  • L-sarcolysine
  • Alanine Stikstof Mosterd
  • L-Phenylalanine Mosterd
  • L-Sarcolysin Phenylalanine mosterd
  • L-Sarcolysine
  • Melphalanum
  • Fenylalanine Mosterd
  • Fenylalanine Stikstof Mosterd
  • Sarcoclorine
  • Sarkolysine
  • WR-19813
  • Melphalan voor injectie-hepatisch toedieningssysteem

Given IV

Given IV

Andere namen:
  • Tepadina
  • Oncotiotepa
  • STEPA
  • TESPA
  • Tespamin
  • TSPA
  • 1,1',1''-fosfinothioylidynetrisaziridine
  • Girostan
  • N,N',N''-triethyleenthiofosforamide
  • Tespamine
  • Thio-Tepa
  • Thiofosfamide
  • Thiofozil
  • Thiofosforamide
  • Thiotef
  • Tifosyl
  • TIO TEF
  • Tio-tef
  • Triethyleen Thiofosforamide
  • Triethyleenthiofosforamide
  • Tris(1-aziridinyl)fosfinesulfide
  • WR 45312
  • Thiofosfoamide
  • SH 105
  • SH-105
  • SH105
  • Tepylute

Given IV

Andere namen:
  • 14.18
  • Qarziba
  • Ch 14.18UTC
  • MOAB Ch14.18
  • monoklonaal antilichaam Ch14.18
  • Unituxin
  • Dinutuximab Beta

Undergo FDG PET

Andere namen:
  • FDG-PET/CT

Undergo stem cell infusion

Andere namen:
  • HSCT
  • HCT
  • Hematopoëtische stamceltransplantatie
  • stamceltransplantatie
  • Hematopoëtische stamcelinfusie
  • Stamceltransplantatie
  • SCT
  • Stamceltransplantatie, NOS
  • HEMATOPOIETISCHE STAMCELTRANSPLANTATIE

Given PO

Andere namen:
  • Amnachting
  • Cistane
  • Claravis
  • Sotret
  • 13-cis-retinoïnezuur
  • 13-cis-retinoaat
  • 13-cis-vitamine A-zuur
  • 13-cRA
  • Absorica
  • Nauwkeurig
  • Accutane
  • cis-retinoïnezuur
  • Isotretinoïne
  • Isotrex
  • Isotrexine
  • Myorisan
  • Neovitamine A
  • Neovitamine A-zuur
  • Oratane
  • Retinoicacid-13-cis
  • Ro 4-3780
  • Ro-4-3780
  • Roaccutan
  • Roaccutane
  • Roacutan
  • ZENATANE

Undergo apheresis

Andere namen:
  • Leukocytoferese
  • Therapeutische leukoferese
  • Leukocyten-adsorptieve aferese
  • Aferese met reductie van witte bloedcellen

Undergo I-MIBG scan

Andere namen:
  • NM
  • Nucleair medicijn
  • scan van de nucleaire geneeskunde
  • radiografie
  • Scannen van radionucliden
  • Scannen
  • Scintigrafie
  • Gamma Scan

Given PO or via NG or G tube

Andere namen:
  • Temodar
  • SCH 52365
  • Temodaal
  • Temcad
  • Methazolasteen
  • RP-46161
  • Temomedac
  • TMZ
  • CCRG-81045
  • Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-
  • M & B 39831
  • M en B 39831
  • Glioteem
  • Temizol

Undergo tumor resection surgery

Experimenteel: Arm B (Dinutuximab in induction)

See detailed description

Given IV

Andere namen:
  • Blastocarb
  • Carboplat
  • Carboplatine Hexal
  • Carboplatino
  • Carboplatina
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatine
  • Paraplatina AQ
  • Platinawas
  • Ribocarbo
  • JM8

Given IV

Andere namen:
  • Cytoxaan
  • CTX
  • (-)-cyclofosfamide
  • 2H-1,3,2-Oxazafosforine, 2-[bis(2-chloorethyl)amino]tetrahydro-, 2-oxide, monohydraat
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Clafeen
  • CP monohydraat
  • CYCLO-cel
  • Cycloblastine
  • Cyclofosfam
  • Cyclofosfamide-monohydraat
  • Cyclofosfamidum
  • Cyclofosfan
  • Cyclofosfaan
  • Cyclofosfanum
  • Cyclostine
  • Cytofosfan
  • Cytofosfaan
  • Fosfaseron
  • Genoxal
  • Genuxaal
  • Ledoxine
  • Mitoxan
  • Neosar
  • Opwekken
  • Syklofosfamide
  • WR-138719
  • Asta B 518
  • B-518
  • B518
  • WR138719
  • Frindovyx

Given IV

Andere namen:
  • CDDP
  • Cis-diamminedichloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatine
  • Platina
  • Abiplatine
  • Blastolem
  • Briplatine
  • Cis-diammine-dichloorplatina
  • Cis-diamminedichloor Platina (II)
  • Cis-diamminedichloorplatina
  • Cis-dichlooramine platina (II)
  • Cis-platina Diamine Dichloride
  • Cis-platina
  • Cis-platina II
  • Cis-platina II diaminedichloride
  • Cisplatine
  • Cisplatyl
  • Citoplatina
  • Citosine
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatine
  • Chloride van Peyrone
  • Zout van Peyrone
  • Plaats
  • Kunststof
  • Platamine
  • Platiblastine
  • Platiblastine-S
  • Platinex
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxaan
  • Platina diamminodichloride
  • Platiraans
  • Platistine
  • Platosine

Undergo bone marrow biopsy

Andere namen:
  • Biopsie van beenmerg
  • Biopsie, beenmerg

Given IV

Andere namen:
  • Adriablastine
  • Hydroxydaunomycine
  • Hydroxyl Daunorubicine
  • Hydroxyldaunorubicine

Given IV

Andere namen:
  • Videorecorder
  • Leurocristine
  • Vincristine
  • LCR

Undergo MRI

Andere namen:
  • MRI
  • Magnetische resonantie
  • Magnetic Resonance Imaging-scan
  • Medische beeldvorming, magnetische resonantie / nucleaire magnetische resonantie
  • DHR
  • MR-beeldvorming
  • MRI scan
  • NMR-beeldvorming
  • NMRI
  • Nucleaire magnetische resonantie beeldvorming
  • Magnetische resonantiebeeldvorming (MRI)
  • sMRI
  • Magnetische resonantiebeeldvorming (procedure)
  • MRI's
  • Structurele MRI

Undergo ECHO

Andere namen:
  • Echocardiografie
  • EG

Undergo MUGA

Andere namen:
  • Blood Pool-scan
  • Equilibrium radionuclide angiografie
  • Gated Blood Pool-beeldvorming
  • MUGA
  • Radionuclide ventriculografie
  • RNVG
  • SYMA scannen
  • Gesynchroniseerde Multigated Acquisitie Scannen
  • MUGA-scan
  • Multi-Gated Acquisitie Scan
  • Radionuclide ventriculogram scan
  • Gated Heart Pool-scan
  • RNV-scan

Undergo bone marrow aspiration

Given IV

Andere namen:
  • Demethyl Epipodofyllotoxine Ethylidine Glucoside
  • EPEG
  • Laatste
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type

Given IV

Andere namen:
  • Hycamptamine
  • Topotecan lacton

Undergo radiation therapy

Andere namen:
  • Radiotherapie bij kanker
  • ENERGY_TYPE
  • Bestralen
  • Bestraald
  • Bestraling
  • Straling
  • Radiotherapie, NOS
  • Radiotherapie
  • RT
  • Therapie, bestraling
  • Energie Type

Undergo blood and urine sample collection

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling

Ancillary studies

Given IV

Andere namen:
  • CB-3025
  • L-PAM
  • L-sarcolysine
  • Alanine Stikstof Mosterd
  • L-Phenylalanine Mosterd
  • L-Sarcolysin Phenylalanine mosterd
  • L-Sarcolysine
  • Melphalanum
  • Fenylalanine Mosterd
  • Fenylalanine Stikstof Mosterd
  • Sarcoclorine
  • Sarkolysine
  • WR-19813
  • Melphalan voor injectie-hepatisch toedieningssysteem

Given IV

Given IV

Andere namen:
  • Tepadina
  • Oncotiotepa
  • STEPA
  • TESPA
  • Tespamin
  • TSPA
  • 1,1',1''-fosfinothioylidynetrisaziridine
  • Girostan
  • N,N',N''-triethyleenthiofosforamide
  • Tespamine
  • Thio-Tepa
  • Thiofosfamide
  • Thiofozil
  • Thiofosforamide
  • Thiotef
  • Tifosyl
  • TIO TEF
  • Tio-tef
  • Triethyleen Thiofosforamide
  • Triethyleenthiofosforamide
  • Tris(1-aziridinyl)fosfinesulfide
  • WR 45312
  • Thiofosfoamide
  • SH 105
  • SH-105
  • SH105
  • Tepylute

Given IV

Andere namen:
  • 14.18
  • Qarziba
  • Ch 14.18UTC
  • MOAB Ch14.18
  • monoklonaal antilichaam Ch14.18
  • Unituxin
  • Dinutuximab Beta

Undergo FDG PET

Andere namen:
  • FDG-PET/CT

Undergo stem cell infusion

Andere namen:
  • HSCT
  • HCT
  • Hematopoëtische stamceltransplantatie
  • stamceltransplantatie
  • Hematopoëtische stamcelinfusie
  • Stamceltransplantatie
  • SCT
  • Stamceltransplantatie, NOS
  • HEMATOPOIETISCHE STAMCELTRANSPLANTATIE

Given PO

Andere namen:
  • Amnachting
  • Cistane
  • Claravis
  • Sotret
  • 13-cis-retinoïnezuur
  • 13-cis-retinoaat
  • 13-cis-vitamine A-zuur
  • 13-cRA
  • Absorica
  • Nauwkeurig
  • Accutane
  • cis-retinoïnezuur
  • Isotretinoïne
  • Isotrex
  • Isotrexine
  • Myorisan
  • Neovitamine A
  • Neovitamine A-zuur
  • Oratane
  • Retinoicacid-13-cis
  • Ro 4-3780
  • Ro-4-3780
  • Roaccutan
  • Roaccutane
  • Roacutan
  • ZENATANE

Undergo apheresis

Andere namen:
  • Leukocytoferese
  • Therapeutische leukoferese
  • Leukocyten-adsorptieve aferese
  • Aferese met reductie van witte bloedcellen

Undergo I-MIBG scan

Andere namen:
  • NM
  • Nucleair medicijn
  • scan van de nucleaire geneeskunde
  • radiografie
  • Scannen van radionucliden
  • Scannen
  • Scintigrafie
  • Gamma Scan

Given PO or via NG or G tube

Andere namen:
  • Temodar
  • SCH 52365
  • Temodaal
  • Temcad
  • Methazolasteen
  • RP-46161
  • Temomedac
  • TMZ
  • CCRG-81045
  • Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-
  • M & B 39831
  • M en B 39831
  • Glioteem
  • Temizol

Undergo tumor resection surgery

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Event free survival (EFS)
Tijdsspanne: Up to 3 years

EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.

Up to 3 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
End of Induction (EOI) response rate
Tijdsspanne: From randomization to end of extended Induction, up to 12 months

The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC)

From randomization to end of extended Induction, up to 12 months
Overall survival (OS)
Tijdsspanne: Up to 3 years

OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive.

Up to 3 years
Incidence of adverse events
Tijdsspanne: Up to 2 years

The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported.

Up to 2 years
GD2 expression
Tijdsspanne: Up to 12 months

Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low.

Up to 12 months

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Association between tumor and host factors and outcomes
Tijdsspanne: Up to 10 years

A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome.

Up to 10 years
Circulating biomarkers and markers of minimal residual disease
Tijdsspanne: Up to 10 years

Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate.

Up to 10 years
Patterns of failure
Tijdsspanne: Up to 10 years

The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test.

Up to 10 years
Effect of telomere maintenance mechanisms
Tijdsspanne: Up to 10 years

A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM.

Up to 10 years
Functional and quality of life outcomes
Tijdsspanne: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy

Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A).

At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
Adequacy of diagnostic biopsy specimens
Tijdsspanne: At time of tissue collection

Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy.

At time of tissue collection
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
Tijdsspanne: Up to 10 years

Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored.

Up to 10 years
Develop and validate deep learning predictors of Induction response (imaging objective)
Tijdsspanne: At diagnosis, EOI, during Extended Induction, and end of Extended Induction

Scans will be given as input to a convolutional neural network trained to predict EOI response.

At diagnosis, EOI, during Extended Induction, and end of Extended Induction
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
Tijdsspanne: Up to 10 years

Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures.

Up to 10 years
Incidence of late toxicities
Tijdsspanne: Up to 10 years

Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion.

Up to 10 years
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
Tijdsspanne: Up to 10 years

The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test.

Up to 10 years
Post-transplant complications
Tijdsspanne: Up to 100 days post-transplant

Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed.

Up to 100 days post-transplant
Associations between end of induction (EOI) response and individual response components
Tijdsspanne: Up to 10 years

Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).

Up to 10 years
Changes in image-defined risk factors (IDRF)
Tijdsspanne: Up to 10 years

The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel.

Up to 10 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Sara M Federico, Children's Oncology Group

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

19 april 2024

Primaire voltooiing (Geschat)

31 december 2029

Studie voltooiing (Geschat)

31 december 2029

Studieregistratiedata

Eerst ingediend

13 december 2023

Eerst ingediend dat voldeed aan de QC-criteria

13 december 2023

Eerst geplaatst (Werkelijk)

15 december 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

29 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • NCI-2023-08530
  • U10CA180886 (Subsidie/contract van de Amerikaanse NIH)
  • NCI-2023-08530 (Register-ID: CTRP (Clinical Trial Reporting Program))
  • ANBL2131 (Andere identificatie: CTEP)
  • ANBL2131 (Andere identificatie: Children's Oncology Group)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren